Tower Bridge Advisors lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 13.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,049 shares of the company’s stock after selling 16,602 shares during the period. Tower Bridge Advisors’ holdings in Merck & Co., Inc. were worth $5,911,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. Krilogy Financial LLC raised its stake in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock worth $201,000 after buying an additional 11 shares in the last quarter. Balentine LLC grew its holdings in shares of Merck & Co., Inc. by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after acquiring an additional 20 shares during the last quarter. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 9,291 shares of the company’s stock worth $595,000 after acquiring an additional 39 shares during the last quarter. Thompson Davis & CO. Inc. grew its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock worth $276,000 after acquiring an additional 40 shares during the last quarter. Finally, Cornerstone Advisory LLP grew its holdings in shares of Merck & Co., Inc. by 0.4% during the second quarter. Cornerstone Advisory LLP now owns 11,110 shares of the company’s stock valued at $712,000 after buying an additional 43 shares in the last quarter. 74.63% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Weir Mirian M. Graddick sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $58.00, for a total value of $290,000.00. Following the sale, the insider now directly owns 101,484 shares in the company, valued at approximately $5,886,072. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total value of $3,697,800.00. Following the completion of the sale, the insider now owns 101,484 shares in the company, valued at $6,254,458.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,500 shares of company stock worth $5,026,025. Corporate insiders own 0.25% of the company’s stock.
A number of brokerages have commented on MRK. Jefferies Group set a $55.00 target price on Merck & Co., Inc. and gave the company a “hold” rating in a research note on Friday, March 23rd. ValuEngine cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. DZ Bank raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley boosted their price objective on Merck & Co., Inc. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Finally, Credit Suisse Group cut their price objective on Merck & Co., Inc. from $67.00 to $66.00 and set an “outperform” rating for the company in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average target price of $66.47.
MRK traded down $1.17 on Friday, hitting $53.36. 12,500,816 shares of the stock traded hands, compared to its average volume of 11,017,954. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $66.41. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $147,023.23, a price-to-earnings ratio of 13.41, a P/E/G ratio of 2.30 and a beta of 0.78.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.04. Merck & Co., Inc. had a return on equity of 28.61% and a net margin of 6.40%. The firm had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. During the same period in the previous year, the company posted $0.89 earnings per share. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. equities research analysts expect that Merck & Co., Inc. will post 4.16 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, April 6th. Stockholders of record on Thursday, March 15th were paid a $0.48 dividend. The ex-dividend date of this dividend was Wednesday, March 14th. This represents a $1.92 annualized dividend and a dividend yield of 3.60%. Merck & Co., Inc.’s dividend payout ratio is currently 48.24%.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/tower-bridge-advisors-sells-16602-shares-of-merck-co-inc-mrk.html.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.